"Global China Ulcerative Colitis Market Overview:
Global China Ulcerative Colitis Market is expected to grow at a significant rate during the forecast period 2025-2032, with 2024 as the base year.
Global China Ulcerative Colitis Market Report 2025 comes with the extensive industry analysis by Introspective Market Research with development components, patterns, flows and sizes. The report also calculates present and past market values to forecast potential market management through the forecast period between 2025-2032.This research study of China Ulcerative Colitis involved the extensive usage of both primary and secondary data sources. This includes the study of various parameters affecting the industry, including the government policy, market environment, competitive landscape, historical data, present trends in the market, technological innovation, upcoming technologies and the technical progress in related industry.
Scope of the China Ulcerative Colitis Market:
The China Ulcerative Colitis Market Research report incorporates value chain analysis for each of the product type. Value chain analysis offers in-depth information about value addition at each stage.The study includes drivers and restraints for China Ulcerative Colitis Market along with their impact on demand during the forecast period. The study also provides key market indicators affecting thegrowth of the market. Research report includes major key player analysis with shares of each player inside market, growth rate and market attractiveness in different endusers/regions. Our study China Ulcerative Colitis Market helps user to make precise decision in order to expand their market presence and increase market share.
By Type, China Ulcerative Colitis market has been segmented into:
5-Aminosalicylates {Mesalazine
Balsalazide
Olsalazine
and Others}
Monoclonal Antibodies {Vedolizumab
Adalimumab
Infliximab
Golimumab
and Ustekinumab}
Steroids {Budesonide
Prednisone
Beclomethasone
Deflazacort
and Others}
Antibiotics
Late Stage Pipeline Molecules {Zeposia
Etrasimod and Others}
and Other Drugs
By Application, China Ulcerative Colitis market has been segmented into:
Oral and Parenteral
Regional Analysis:
North America (U.S., Canada, Mexico)
Europe (Germany, U.K., France, Italy, Russia, Spain, Rest of Europe)
Asia-Pacific (China, India, Japan, Singapore, Australia, New Zealand, Rest of APAC)
South America (Brazil, Argentina, Rest of SA)
Middle East & Africa (Turkey, Saudi Arabia, Iran, UAE, Africa, Rest of MEA)
Competitive Landscape:
Competitive analysis is the study of strength and weakness, market investment, market share, market sales volume, market trends of major players in the market.The China Ulcerative Colitis market study focused on including all the primary level, secondary level and tertiary level competitors in the report. The data generated by conducting the primary and secondary research.The report covers detail analysis of driver, constraints and scope for new players entering the China Ulcerative Colitis market.
Top Key Players Covered in China Ulcerative Colitis market are:
AbbVie Inc
Celltrion Healthcare
Johnson & Johnson Services
Inc.
F. Hoffmann-La Roche AG
Arena Pharmaceuticals
Takeda Pharmaceuticals Company Ltd.
GlaxoSmithKline Plc.
Eli Lilly and Company
AstraZeneca
Pfizer Inc.
Amgen Inc.
BRISTOL-MYERS SQUIBB
ZERIA Pharmaceutical Co. Ltd
InDex Pharmaceuticals Holding AB
Mitsubishi Tanabe Pharma Corporation
Salix Pharmaceuticals
Boehringer Ingelheim International GmbH
Teva Pharmaceutical Industries Ltd.
EA Pharma Co. Ltd
Theravance Biopharma
HUTCHMED
"
Chapter 1: Introduction
1.1 Scope and Coverage
Chapter 2:Executive Summary
Chapter 3: Market Landscape
3.1 Market Dynamics
3.1.1 Drivers
3.1.2 Restraints
3.1.3 Opportunities
3.1.4 Challenges
3.2 Market Trend Analysis
3.3 PESTLE Analysis
3.4 Porter's Five Forces Analysis
3.5 Industry Value Chain Analysis
3.6 Ecosystem
3.7 Regulatory Landscape
3.8 Price Trend Analysis
3.9 Patent Analysis
3.10 Technology Evolution
3.11 Investment Pockets
3.12 Import-Export Analysis
Chapter 4: China Ulcerative Colitis Market by Type
4.1 China Ulcerative Colitis Market Snapshot and Growth Engine
4.2 China Ulcerative Colitis Market Overview
4.3 5-Aminosalicylates {Mesalazine
4.3.1 Introduction and Market Overview
4.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.3.3 Key Market Trends, Growth Factors and Opportunities
4.3.4 5-Aminosalicylates {Mesalazine: Geographic Segmentation Analysis
4.4 Balsalazide
4.4.1 Introduction and Market Overview
4.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.4.3 Key Market Trends, Growth Factors and Opportunities
4.4.4 Balsalazide: Geographic Segmentation Analysis
4.5 Olsalazine
4.5.1 Introduction and Market Overview
4.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.5.3 Key Market Trends, Growth Factors and Opportunities
4.5.4 Olsalazine: Geographic Segmentation Analysis
4.6 and Others}
4.6.1 Introduction and Market Overview
4.6.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.6.3 Key Market Trends, Growth Factors and Opportunities
4.6.4 and Others}: Geographic Segmentation Analysis
4.7 Monoclonal Antibodies {Vedolizumab
4.7.1 Introduction and Market Overview
4.7.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.7.3 Key Market Trends, Growth Factors and Opportunities
4.7.4 Monoclonal Antibodies {Vedolizumab: Geographic Segmentation Analysis
4.8 Adalimumab
4.8.1 Introduction and Market Overview
4.8.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.8.3 Key Market Trends, Growth Factors and Opportunities
4.8.4 Adalimumab: Geographic Segmentation Analysis
4.9 Infliximab
4.9.1 Introduction and Market Overview
4.9.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.9.3 Key Market Trends, Growth Factors and Opportunities
4.9.4 Infliximab: Geographic Segmentation Analysis
4.10 Golimumab
4.10.1 Introduction and Market Overview
4.10.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.10.3 Key Market Trends, Growth Factors and Opportunities
4.10.4 Golimumab: Geographic Segmentation Analysis
4.11 and Ustekinumab}
4.11.1 Introduction and Market Overview
4.11.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.11.3 Key Market Trends, Growth Factors and Opportunities
4.11.4 and Ustekinumab}: Geographic Segmentation Analysis
4.12 Steroids {Budesonide
4.12.1 Introduction and Market Overview
4.12.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.12.3 Key Market Trends, Growth Factors and Opportunities
4.12.4 Steroids {Budesonide: Geographic Segmentation Analysis
4.13 Prednisone
4.13.1 Introduction and Market Overview
4.13.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.13.3 Key Market Trends, Growth Factors and Opportunities
4.13.4 Prednisone: Geographic Segmentation Analysis
4.14 Beclomethasone
4.14.1 Introduction and Market Overview
4.14.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.14.3 Key Market Trends, Growth Factors and Opportunities
4.14.4 Beclomethasone: Geographic Segmentation Analysis
4.15 Deflazacort
4.15.1 Introduction and Market Overview
4.15.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.15.3 Key Market Trends, Growth Factors and Opportunities
4.15.4 Deflazacort: Geographic Segmentation Analysis
4.16 and Others}
4.16.1 Introduction and Market Overview
4.16.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.16.3 Key Market Trends, Growth Factors and Opportunities
4.16.4 and Others}: Geographic Segmentation Analysis
4.17 Antibiotics
4.17.1 Introduction and Market Overview
4.17.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.17.3 Key Market Trends, Growth Factors and Opportunities
4.17.4 Antibiotics: Geographic Segmentation Analysis
4.18 Late Stage Pipeline Molecules {Zeposia
4.18.1 Introduction and Market Overview
4.18.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.18.3 Key Market Trends, Growth Factors and Opportunities
4.18.4 Late Stage Pipeline Molecules {Zeposia: Geographic Segmentation Analysis
4.19 Etrasimod and Others}
4.19.1 Introduction and Market Overview
4.19.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.19.3 Key Market Trends, Growth Factors and Opportunities
4.19.4 Etrasimod and Others}: Geographic Segmentation Analysis
4.20 and Other Drugs
4.20.1 Introduction and Market Overview
4.20.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.20.3 Key Market Trends, Growth Factors and Opportunities
4.20.4 and Other Drugs: Geographic Segmentation Analysis
Chapter 5: China Ulcerative Colitis Market by Application
5.1 China Ulcerative Colitis Market Snapshot and Growth Engine
5.2 China Ulcerative Colitis Market Overview
5.3 Oral and Parenteral
5.3.1 Introduction and Market Overview
5.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.3.3 Key Market Trends, Growth Factors and Opportunities
5.3.4 Oral and Parenteral: Geographic Segmentation Analysis
Chapter 6: Company Profiles and Competitive Analysis
6.1 Competitive Landscape
6.1.1 Competitive Benchmarking
6.1.2 China Ulcerative Colitis Market Share by Manufacturer (2023)
6.1.3 Industry BCG Matrix
6.1.4 Heat Map Analysis
6.1.5 Mergers and Acquisitions
6.2 ABBVIE INC
6.2.1 Company Overview
6.2.2 Key Executives
6.2.3 Company Snapshot
6.2.4 Role of the Company in the Market
6.2.5 Sustainability and Social Responsibility
6.2.6 Operating Business Segments
6.2.7 Product Portfolio
6.2.8 Business Performance
6.2.9 Key Strategic Moves and Recent Developments
6.2.10 SWOT Analysis
6.3 CELLTRION HEALTHCARE
6.4 JOHNSON & JOHNSON SERVICES
6.5 INC.
6.6 F. HOFFMANN-LA ROCHE AG
6.7 ARENA PHARMACEUTICALS
6.8 TAKEDA PHARMACEUTICALS COMPANY LTD.
6.9 GLAXOSMITHKLINE PLC.
6.10 ELI LILLY AND COMPANY
6.11 ASTRAZENECA
6.12 PFIZER INC.
6.13 AMGEN INC.
6.14 BRISTOL-MYERS SQUIBB
6.15 ZERIA PHARMACEUTICAL CO.
6.16 LTD.
6.17 INDEX PHARMACEUTICALS HOLDING AB
6.18 MITSUBISHI TANABE PHARMA CORPORATION
6.19 SALIX PHARMACEUTICALS
6.20 BOEHRINGER INGELHEIM INTERNATIONAL GMBH
6.21 TEVA PHARMACEUTICAL INDUSTRIES LTD.
6.22 EA PHARMA CO.
6.23 LTD.
6.24 THERAVANCE BIOPHARMA
6.25 AND HUTCHMED
Chapter 7: Global China Ulcerative Colitis Market By Region
7.1 Overview
7.2. North America China Ulcerative Colitis Market
7.2.1 Key Market Trends, Growth Factors and Opportunities
7.2.2 Top Key Companies
7.2.3 Historic and Forecasted Market Size by Segments
7.2.4 Historic and Forecasted Market Size By Type
7.2.4.1 5-Aminosalicylates {Mesalazine
7.2.4.2 Balsalazide
7.2.4.3 Olsalazine
7.2.4.4 and Others}
7.2.4.5 Monoclonal Antibodies {Vedolizumab
7.2.4.6 Adalimumab
7.2.4.7 Infliximab
7.2.4.8 Golimumab
7.2.4.9 and Ustekinumab}
7.2.4.10 Steroids {Budesonide
7.2.4.11 Prednisone
7.2.4.12 Beclomethasone
7.2.4.13 Deflazacort
7.2.4.14 and Others}
7.2.4.15 Antibiotics
7.2.4.16 Late Stage Pipeline Molecules {Zeposia
7.2.4.17 Etrasimod and Others}
7.2.4.18 and Other Drugs
7.2.5 Historic and Forecasted Market Size By Application
7.2.5.1 Oral and Parenteral
7.2.6 Historic and Forecast Market Size by Country
7.2.6.1 US
7.2.6.2 Canada
7.2.6.3 Mexico
7.3. Eastern Europe China Ulcerative Colitis Market
7.3.1 Key Market Trends, Growth Factors and Opportunities
7.3.2 Top Key Companies
7.3.3 Historic and Forecasted Market Size by Segments
7.3.4 Historic and Forecasted Market Size By Type
7.3.4.1 5-Aminosalicylates {Mesalazine
7.3.4.2 Balsalazide
7.3.4.3 Olsalazine
7.3.4.4 and Others}
7.3.4.5 Monoclonal Antibodies {Vedolizumab
7.3.4.6 Adalimumab
7.3.4.7 Infliximab
7.3.4.8 Golimumab
7.3.4.9 and Ustekinumab}
7.3.4.10 Steroids {Budesonide
7.3.4.11 Prednisone
7.3.4.12 Beclomethasone
7.3.4.13 Deflazacort
7.3.4.14 and Others}
7.3.4.15 Antibiotics
7.3.4.16 Late Stage Pipeline Molecules {Zeposia
7.3.4.17 Etrasimod and Others}
7.3.4.18 and Other Drugs
7.3.5 Historic and Forecasted Market Size By Application
7.3.5.1 Oral and Parenteral
7.3.6 Historic and Forecast Market Size by Country
7.3.6.1 Bulgaria
7.3.6.2 The Czech Republic
7.3.6.3 Hungary
7.3.6.4 Poland
7.3.6.5 Romania
7.3.6.6 Rest of Eastern Europe
7.4. Western Europe China Ulcerative Colitis Market
7.4.1 Key Market Trends, Growth Factors and Opportunities
7.4.2 Top Key Companies
7.4.3 Historic and Forecasted Market Size by Segments
7.4.4 Historic and Forecasted Market Size By Type
7.4.4.1 5-Aminosalicylates {Mesalazine
7.4.4.2 Balsalazide
7.4.4.3 Olsalazine
7.4.4.4 and Others}
7.4.4.5 Monoclonal Antibodies {Vedolizumab
7.4.4.6 Adalimumab
7.4.4.7 Infliximab
7.4.4.8 Golimumab
7.4.4.9 and Ustekinumab}
7.4.4.10 Steroids {Budesonide
7.4.4.11 Prednisone
7.4.4.12 Beclomethasone
7.4.4.13 Deflazacort
7.4.4.14 and Others}
7.4.4.15 Antibiotics
7.4.4.16 Late Stage Pipeline Molecules {Zeposia
7.4.4.17 Etrasimod and Others}
7.4.4.18 and Other Drugs
7.4.5 Historic and Forecasted Market Size By Application
7.4.5.1 Oral and Parenteral
7.4.6 Historic and Forecast Market Size by Country
7.4.6.1 Germany
7.4.6.2 UK
7.4.6.3 France
7.4.6.4 Netherlands
7.4.6.5 Italy
7.4.6.6 Russia
7.4.6.7 Spain
7.4.6.8 Rest of Western Europe
7.5. Asia Pacific China Ulcerative Colitis Market
7.5.1 Key Market Trends, Growth Factors and Opportunities
7.5.2 Top Key Companies
7.5.3 Historic and Forecasted Market Size by Segments
7.5.4 Historic and Forecasted Market Size By Type
7.5.4.1 5-Aminosalicylates {Mesalazine
7.5.4.2 Balsalazide
7.5.4.3 Olsalazine
7.5.4.4 and Others}
7.5.4.5 Monoclonal Antibodies {Vedolizumab
7.5.4.6 Adalimumab
7.5.4.7 Infliximab
7.5.4.8 Golimumab
7.5.4.9 and Ustekinumab}
7.5.4.10 Steroids {Budesonide
7.5.4.11 Prednisone
7.5.4.12 Beclomethasone
7.5.4.13 Deflazacort
7.5.4.14 and Others}
7.5.4.15 Antibiotics
7.5.4.16 Late Stage Pipeline Molecules {Zeposia
7.5.4.17 Etrasimod and Others}
7.5.4.18 and Other Drugs
7.5.5 Historic and Forecasted Market Size By Application
7.5.5.1 Oral and Parenteral
7.5.6 Historic and Forecast Market Size by Country
7.5.6.1 China
7.5.6.2 India
7.5.6.3 Japan
7.5.6.4 South Korea
7.5.6.5 Malaysia
7.5.6.6 Thailand
7.5.6.7 Vietnam
7.5.6.8 The Philippines
7.5.6.9 Australia
7.5.6.10 New Zealand
7.5.6.11 Rest of APAC
7.6. Middle East & Africa China Ulcerative Colitis Market
7.6.1 Key Market Trends, Growth Factors and Opportunities
7.6.2 Top Key Companies
7.6.3 Historic and Forecasted Market Size by Segments
7.6.4 Historic and Forecasted Market Size By Type
7.6.4.1 5-Aminosalicylates {Mesalazine
7.6.4.2 Balsalazide
7.6.4.3 Olsalazine
7.6.4.4 and Others}
7.6.4.5 Monoclonal Antibodies {Vedolizumab
7.6.4.6 Adalimumab
7.6.4.7 Infliximab
7.6.4.8 Golimumab
7.6.4.9 and Ustekinumab}
7.6.4.10 Steroids {Budesonide
7.6.4.11 Prednisone
7.6.4.12 Beclomethasone
7.6.4.13 Deflazacort
7.6.4.14 and Others}
7.6.4.15 Antibiotics
7.6.4.16 Late Stage Pipeline Molecules {Zeposia
7.6.4.17 Etrasimod and Others}
7.6.4.18 and Other Drugs
7.6.5 Historic and Forecasted Market Size By Application
7.6.5.1 Oral and Parenteral
7.6.6 Historic and Forecast Market Size by Country
7.6.6.1 Turkey
7.6.6.2 Bahrain
7.6.6.3 Kuwait
7.6.6.4 Saudi Arabia
7.6.6.5 Qatar
7.6.6.6 UAE
7.6.6.7 Israel
7.6.6.8 South Africa
7.7. South America China Ulcerative Colitis Market
7.7.1 Key Market Trends, Growth Factors and Opportunities
7.7.2 Top Key Companies
7.7.3 Historic and Forecasted Market Size by Segments
7.7.4 Historic and Forecasted Market Size By Type
7.7.4.1 5-Aminosalicylates {Mesalazine
7.7.4.2 Balsalazide
7.7.4.3 Olsalazine
7.7.4.4 and Others}
7.7.4.5 Monoclonal Antibodies {Vedolizumab
7.7.4.6 Adalimumab
7.7.4.7 Infliximab
7.7.4.8 Golimumab
7.7.4.9 and Ustekinumab}
7.7.4.10 Steroids {Budesonide
7.7.4.11 Prednisone
7.7.4.12 Beclomethasone
7.7.4.13 Deflazacort
7.7.4.14 and Others}
7.7.4.15 Antibiotics
7.7.4.16 Late Stage Pipeline Molecules {Zeposia
7.7.4.17 Etrasimod and Others}
7.7.4.18 and Other Drugs
7.7.5 Historic and Forecasted Market Size By Application
7.7.5.1 Oral and Parenteral
7.7.6 Historic and Forecast Market Size by Country
7.7.6.1 Brazil
7.7.6.2 Argentina
7.7.6.3 Rest of SA
Chapter 8 Analyst Viewpoint and Conclusion
8.1 Recommendations and Concluding Analysis
8.2 Potential Market Strategies
Chapter 9 Research Methodology
9.1 Research Process
9.2 Primary Research
9.3 Secondary Research
China Ulcerative Colitis Scope:
|
Report Data
|
China Ulcerative Colitis Market
|
|
China Ulcerative Colitis Market Size in 2025
|
USD XX million
|
|
China Ulcerative Colitis CAGR 2025 - 2032
|
XX%
|
|
China Ulcerative Colitis Base Year
|
2024
|
|
China Ulcerative Colitis Forecast Data
|
2025 - 2032
|
|
Segments Covered
|
By Type, By Application, And by Regions
|
|
Regional Scope
|
North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
|
|
Key Companies Profiled
|
AbbVie Inc, Celltrion Healthcare, Johnson & Johnson Services, Inc., F. Hoffmann-La Roche AG, Arena Pharmaceuticals, Takeda Pharmaceuticals Company Ltd., GlaxoSmithKline Plc., Eli Lilly and Company, AstraZeneca, Pfizer Inc., Amgen Inc., BRISTOL-MYERS SQUIBB, ZERIA Pharmaceutical Co., Ltd., InDex Pharmaceuticals Holding AB, Mitsubishi Tanabe Pharma Corporation, Salix Pharmaceuticals, Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., EA Pharma Co., Ltd., Theravance Biopharma, and HUTCHMED.
|
|
Key Segments
|
By Type
5-Aminosalicylates {Mesalazine
Balsalazide
Olsalazine
and Others}
Monoclonal Antibodies {Vedolizumab
Adalimumab
Infliximab
Golimumab
and Ustekinumab}
Steroids {Budesonide
Prednisone
Beclomethasone
Deflazacort
and Others}
Antibiotics
Late Stage Pipeline Molecules {Zeposia
Etrasimod and Others}
and Other Drugs
By Applications
Oral and Parenteral
|
